Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine (GSK1674330A) in Healthy Female Subjects Aged 18-25 Years.
Brief Summary: Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb). This infection may go away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. GlaxoSmithKline Biologicals has developed a HPV vaccine against the oncogenic types HPV-16 and HPV-18 formulated with the AS04 adjuvant (control vaccine) and is also evaluating novel HPV vaccines formulations. This study will evaluate a novel GSK Biologicals' HPV vaccine (GSK1674330A) in terms of safety and immunogenicity compared to the control vaccine. There will be different levels of blinding in the study.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: qHPV Vaccine; Type: EXPERIMENTAL; Interventions: Biological: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: placebo (unspecified) | Intervention Type: BIOLOGICAL; Name: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): qHPV Vaccine | Intervention Type: BIOLOGICAL; Name: Comparator: placebo (unspecified); Assigned to Arm(s): Placebo
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group F; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix TM | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV vaccine (GSK1674330A); Assigned to Arm(s): Group A, Group B, Group C, Group D, Group E | Intervention Type: BIOLOGICAL; Name: Cervarix TM; Assigned to Arm(s): Group F
C: Arm Label: qHPV Vaccine in Base Study; Type: EXPERIMENTAL; Interventions: Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | Arm Label: Placebo in Base Study; Type: PLACEBO_COMPARATOR; Interventions: Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Biological: Comparator: Placebo | Intervention Type: BIOLOGICAL; Name: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine; Assigned to Arm(s): Placebo in Base Study, qHPV Vaccine in Base Study | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): Placebo in Base Study
D: Arm Label: Cervarix 1/Placebo Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 1/Placebo/Cervarix 1 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 2/Placebo/Cervarix 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix 1/Placebo Group, Cervarix 1/Placebo/Cervarix 1 Group, Cervarix 2 Group, Cervarix 2/Placebo/Cervarix 2 Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cervarix 1/Placebo Group, Cervarix 1/Placebo/Cervarix 1 Group, Cervarix 2/Placebo/Cervarix 2 Group

Answer: B